Use of multikinase inhibitors/lenvatinib in patients with high cardiovascular risk/vasculopathy and radioiodine refractory‐differentiated thyroid cancer
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.5127
Abstract: Antiangiogenic tyrosine kinase inhibitors are the treatment of choice in radioiodine refractory‐differentiated thyroid cancer (RR‐DTC). Nevertheless, these therapies present class toxicities that may impact their feasibility and patient's quality of life. Their mechanism of action… read more here.
Keywords: refractory differentiated; differentiated thyroid; thyroid cancer; radioiodine refractory ... See more keywords
Radioiodine refractory differentiated thyroid cancer.
Sign Up to like & getrecommendations! Published in 2018 at "Critical reviews in oncology/hematology"
DOI: 10.1016/j.critrevonc.2018.03.012
Abstract: Differentiated thyroid cancer (DTC) is usually curable with surgery, radioactive iodine (RAI), and thyroid-stimulating hormone (TSH) suppression. However, local recurrence and/or distant metastases occur in approximately 15% of cases during follow-up, and nearly two-thirds of… read more here.
Keywords: dtc; refractory differentiated; differentiated thyroid; thyroid cancer ... See more keywords
Efficacy and safety of multi-kinase inhibitors in patients with radioiodine-refractory differentiated thyroid cancer: a systematic review and meta-analysis of clinical trials
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Anticancer Therapy"
DOI: 10.1080/14737140.2022.2102000
Abstract: ABSTRACT Objectives Radioiodine-refractory differentiated thyroid cancer (RAI-rDTC) has frequently been associated with poor prognosis. We conducted a meta-analysis of published randomized controlled trials to evaluate multi-kinase inhibitors’ efficacy and safety profile treatment. Methods A comprehensive… read more here.
Keywords: refractory differentiated; meta analysis; differentiated thyroid; thyroid cancer ... See more keywords
Can 99Tcm-3PRGD2(ανβ3) and 18F-FDG dual-tracer molecular imaging change the therapeutic strategy for progressive refractory differentiated thyroid cancer: Case report
Sign Up to like & getrecommendations! Published in 2023 at "Medicine"
DOI: 10.1097/md.0000000000032751
Abstract: Rationale: The management of radioiodine refractory differentiated thyroid cancer (RAIR-DTC) represents a major challenge in thyroid cancer. The American Thyroid Association guidelines recommend the use of tyrosine kinase inhibitors (TKIs) for RAIR-DTC that does not… read more here.
Keywords: 99tcm 3prgd2; refractory differentiated; rair; thyroid cancer ... See more keywords
177Lu-DOTATATE Therapy in Radioiodine-refractory Differentiated Thyroid Cancer: A Single Center Experience
Sign Up to like & getrecommendations! Published in 2018 at "Clinical Nuclear Medicine"
DOI: 10.1097/rlu.0000000000002219
Abstract: Introduction Patients with radioiodine-refractory differentiated thyroid cancer (RrDTC) have a rather poor prognosis and are in need of novel treatments. As RrDTCs can in some cases express somatostatin receptors (SSRT), targeting of these receptors by… read more here.
Keywords: refractory differentiated; 177lu dotatate; differentiated thyroid; dotatate ... See more keywords
131I-radioisotope modified in PEGylation metal organic frameworks for sensitization in refractory differentiated thyroid cancer treatment.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of biomaterials applications"
DOI: 10.1177/08853282211029822
Abstract: Radiation therapy for cancer can lead to off-target toxicity and can be ineffective against refractory differentiated thyroid cancer. The nanoscale metal organic frameworks (NMOFs) have shown great potential in cancer diagnostic and treatment due to… read more here.
Keywords: radioisotope; refractory differentiated; differentiated thyroid; thyroid cancer ... See more keywords
An exploratory phase II clinical trial of apatinib in progressive radioiodine refractory differentiated thyroid cancer.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.e18094
Abstract: e18094Background: Anti-angiogenic TKI is the most potential effective strategy for patients (pts) with progressive radioiodine refractory differentiated thyroid cancer (RAIR-DTC). This phase II tri... read more here.
Keywords: progressive radioiodine; refractory differentiated; differentiated thyroid; thyroid cancer ... See more keywords
Radiomics-based prediction of response to multikinase inhibitors in radioiodine-refractory differentiated thyroid cancer patients.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.6077
Abstract: 6077 Background: Antiangiogenic tyrosine kinase inhibitors (TKIs) represent the first-line treatment for radioiodine-refractory differentiated thyroid cancer (RR-DTC). Currently, no predictive factors for the activity of these drugs are available. We investigated whether radiomics may have… read more here.
Keywords: response; refractory differentiated; response tkis; differentiated thyroid ... See more keywords
Baseline Tumour Size as a Prognostic Factor for Radioiodine-refractory Differentiated Thyroid Cancer Treated With Lenvatinib
Sign Up to like & getrecommendations! Published in 2021 at "AntiCancer Research"
DOI: 10.21873/anticanres.14932
Abstract: Background/Aim: Lenvatinib is standard therapy for radioiodine-refractory differentiated thyroid cancer (RR-DTC), although the optimal timing for starting treatment is still controversial. The aim of this study was to evaluate the prognostic impact of baseline tumour… read more here.
Keywords: baseline tumour; refractory differentiated; differentiated thyroid; thyroid cancer ... See more keywords
Sorafenib and Lenvatinib Treatment for Metastasis/Recurrence of Radioactive Iodine-refractory Differentiated Thyroid Carcinoma
Sign Up to like & getrecommendations! Published in 2021 at "In Vivo"
DOI: 10.21873/invivo.12350
Abstract: Background/Aim: Radioactive iodine-refractory differentiated thyroid carcinoma (RR-DTC) has been treated with multi-kinase inhibitors (MKIs), e.g., sorafenib (SOR) and lenvatinib (LEN). We analyzed the outcomes of RR-DTC patients who underwent SOR or LEN treatment at Kuma… read more here.
Keywords: radioactive iodine; refractory differentiated; treatment; differentiated thyroid ... See more keywords
Do Molecular Profiles of Primary Versus Metastatic Radioiodine Refractory Differentiated Thyroid Cancer Differ?
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Endocrinology"
DOI: 10.3389/fendo.2021.623182
Abstract: Management of metastatic radioiodine refractory differentiated thyroid cancer (DTC) can be a therapeutic challenge. Generally, little is known about the paired molecular profile of the primary tumor and the metastases and whether they harbor the… read more here.
Keywords: refractory differentiated; differentiated thyroid; thyroid cancer; radioiodine ... See more keywords